Malawi has taken a bold step toward strengthening its health security and economic resilience following a landmark partnership between MUST and Rephaiah, an Icelandic pharmaceutical firm, to establish local drug manufacturing plant at the university’s industrial park. 

The collaboration marks a transformative moment for the nation, positioning Malawi to reduce reliance on imported medicines while building a sustainable, innovation-driven pharmaceutical sector.

At the signing ceremony, MUST Council Vice Chairperson, Ms Thokozile Kuwali described the initiative as a strategic national project with far-reaching benefits. 

She emphasized that local production of medicines will help the country save scarce foreign exchange, strengthen industrial capacity, and create opportunities for exports in the regional market. 

According to Kuwali, the partnership reflects the university’s commitment to translating research into tangible solutions that directly improve livelihoods and accelerate national development.

Rephaiah Chairperson Professor Sveinbjorn Gizurarson highlighted the significance of the collaboration in raising pharmaceutical standards in the country. 

He noted that the project will not only deliver high-quality medicines but also facilitate technology transfer, strengthen quality assurance systems, and enhance drug security.

By working closely with local scientists, Gizurarson said, the initiative will nurture skills development and foster a new generation of pharmaceutical innovators in Malawi.

The Government of Iceland, through Ambassador David Bjarnason, reaffirmed its support for the partnership, underscoring the importance of global cooperation in advancing health systems. 

Ambassador Bjarnason said the collaboration will deepen ties between academia and industry, ensuring that research breakthroughs translate into scalable manufacturing solutions that benefit both Malawi and the wider region.

On behalf of the government, Principal Secretary for Industrialisation in the Ministry of Industrialisation, Business, Trade and Tourism, Dr Bright Molande, commended MUST for demonstrating its growing role as a hub of production, innovation, and job creation.

He said government looks forward to a day when public universities will be paying dividends instead of asking for funds due to their involvement in industrialisation and entrepreneurship.

He noted that the project aligns with Malawi’s broader industrialization agenda and will contribute to building a competitive knowledge-based economy.

Beyond its economic impact, the partnership symbolizes a powerful shift toward self-reliance in healthcare. 

By producing essential medicines locally, Malawi will improve access, stabilize supply chains, and strengthen its preparedness for future health challenges. 

The initiative also reinforces MUST’s reputation as a university that not only educates but actively drives solutions to national priorities.

The ceremony began with a site visit to MUST’s industrial park, where the pharmaceutical manufacturing facility will be planted.

As construction and operational planning move forward, the collaboration is expected to inspire confidence among investors, researchers, and students alike. 

It stands as a testament to what can be achieved when academia, government, and international partners unite around a shared vision a healthier, more prosperous Malawi powered by homegrown innovation.